The article written by Caroline Keohane explores the “Femtech” industry, which focuses on innovative solutions for women’s health issues. In the Historic Inequality in Medicine paragraph, Aspivix’s solution is introduced as having finally developed a device that could impact positively women’s health. Ikram Guerd, VP of Global Marketing is also sharing her experience when pitching to investors and their initial reaction.

While these health problems have always existed for women, they have never been addressed, or if they have, the current standards of care have not been innovated on due to a lack of research and funding and do not take advantage of the modern technologies available to make women’s lives easier and more comfortable.

Read the full article at https://venturistbysvs.substack.com/p/exploring-femtech to understand the challenges, innovations, and immense potential of Femtech.

Figure 1

An example is the tenaculum, shown above in Figure 1. It is a long metal, scissor-like tool with sharp hooks on the ends used in many intrauterine procedures.

This tool was invented during the Civil War and has not been innovated since, despite causing 90% of women unnecessary pain during procedures—pain so severe it deterred up to 30% of women from getting the procedures done.

It was not until 2015, when Aspivix, a Swiss medical device company, was founded, that a simple, effective, and affordable solution was created, decreasing pain by 73% and bleeding by 78%. It was not a revolutionary device, but no one had considered making it.

There is a gap that Femtech companies like Aspivix are working to fill. The market is large, and the space is ripe for innovation. However, securing funding is an uphill battle for these companies due to historical inequalities, data barriers, censorship, and lack of education.”

About the Venturist:
The Venturist is the in-house publication team of SVS (Strategic Venture Society) , offering a Gen Z take on tech/venture capital trends and blazing startups.